CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.91 +0.04 (+4.42%)
As of: Oct 21, 2026 · 3:59 PM EDT

CytoMed Therapeutics (GDTC) Receivables (2021 - 2026)

Updated

CytoMed Therapeutics (GDTC) recorded Receivables of $1.78 million in Q2 2026, up 69.9% from $1.05 million a year earlier.

Analysis

CytoMed Therapeutics (GDTC) Receivables (2021 - 2026) Analysis & Trends

At the end of FY2025, CytoMed Therapeutics reported Receivables of $1.57 million, up 37.3% from FY2024.

  • Annual Receivables has a four-year compound annual growth rate of 4.1% (FY2021 to FY2025).
  • Across earlier years, Receivables came in at $1.15 million in FY2024 (-40.8%), $1.94 million in FY2023 (+21.3%), $1.6 million in FY2022 (+19.0%) and $1.34 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,167.17 Bn 1,135.76 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 633.70 Bn 552.23 Bn 17.26 Bn 19.05 Bn
3 AbbVie 503.94 Bn 477.06 Bn 12.70 Bn 13.82 Bn
4 Merck 378.10 Bn 332.47 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 303.72 Bn 267.71 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 266.46 Bn 240.15 Bn 12.86 Bn 15.68 Bn
7 Amgen 241.07 Bn 196.47 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 194.22 Bn 168.41 Bn 6.22 Bn 5.06 Bn
9 Pfizer 172.39 Bn 119.04 Bn 10.94 Bn 12.49 Bn
10 CytoMed Therapeutics 10.29 Mn 1.11 Mn - 2.11 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.11 Mn
Dec 31, 2025 1.60 Mn
Jun 30, 2025 1.05 Mn
Dec 31, 2024 1.13 Mn
Dec 31, 2023 1.03 Mn
Dec 31, 2022 789,293.77
Dec 31, 2021 583,986.38
API Access

CytoMed Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=GDTC&period=max&api_key=YOUR_API_KEY